Events
Solebury Trout Summer Investor tour
July 9. 2019 in Paris. Jean-Jacques Garaud, CEO at Inotrem, will be a speaker at the Solebury Trout Summer Investor tour, hosted by Andera Partners
Menu
A novel approach to target inflammatory diseases
A novel approach to target inflammatory diseases
Inotrem is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses.
Inotrem identified the TREM-1 pathway as a key factor causing unbalanced inflammatory responses. The company focuses on the therapeutic tools derived from knowledge of the biology of TREM-1 pathway.
Through its proprietary technology platform, Inotrem has developed the first-in-class clinical TREM-1 inhibitor, nangibotide (LR12), with applications in a number of indications such as septic shock or myocardial infarction.
INOTREM SA is a biopharmaceutical company discovering and developing first-in-class immunotherapies for the treatment of inflammatory diseases.
A first clinical trial to assess the safety, tolerability and pharmacokinetics of MOTREM in healthy volunteers is currently ongoing.
Events
Solebury Trout Summer Investor tour
July 9. 2019 in Paris. Jean-Jacques Garaud, CEO at Inotrem, will be a speaker at the Solebury Trout Summer Investor tour, hosted by Andera Partners